Silence Therapeutics (SLN) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.
- Silence Therapeutics' Income towards Parent Company rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1562.71% up from last year.
- As of Q3 2025, Silence Therapeutics' Income towards Parent Company stood at -$21.0 million, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Income towards Parent Company ranged from a high of $12.3 million in Q4 2024 and a low of -$39.2 million during Q3 2024
- Moreover, its 5-year median value for Income towards Parent Company was -$16.6 million (2021), whereas its average is -$16.5 million.
- As far as peak fluctuations go, Silence Therapeutics' Income towards Parent Company soared by 16622.85% in 2024, and later tumbled by 56837.47% in 2025.
- Silence Therapeutics' Income towards Parent Company (Quarter) stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
- Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.